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The proto-oncogene c-KIT encodes a growth factor
receptor, KIT, with ligand-dependent tyrosine kinase
activity that is expressed by several cell types including
mast cells. c-KIT juxtamembrane coding region
mutations causing constitutive activation of KIT are
capable of transforming cell lines and have been identi-
fied in a human mast cell line and in situ in human
gastrointestinal stromal tumors, but have not been
demonstrated in situ in neoplastic mast cells from any
species. To determine whether c-KIT juxtamembrane
mutations occur in the development of mast cell
neoplasms, we examined canine mastocytomas, which
are among the most common tumors of dogs and
which often behave in a malignant fashion, unlike
human solitary mastocytomas. Sequencing of c-KIT
cDNA generated from tumor tissues removed from
seven dogs revealed that three of the tumors contained
The c-KIT proto-oncogene encodes the KIT cell-surface receptor, which is comprised of an extracellulardomain containing five immunoglobulin-like loops,a transmembrane domain, and a cytoplasmic domainconsisting of a juxtamembrane region, a kinase domain
divided into adenosine triphosphate (ATP)-binding and phospho-
transferase subdomains by a kinase insert, and a carboxy-terminal
tail (Yarden et al, 1987; Qiu et al, 1988). KIT shares sequence and
domain organization similarity with the receptors for colony-
stimulating factor-1 and platelet-derived growth factor, the three
forming the type III receptor tyrosine kinase subfamily (Yarden
et al, 1987; Qiu et al, 1988; Ullrich and Schlessinger, 1990). The
cognate ligand for KIT, variously named stem cell factor (SCF),
mast cell growth factor, steel factor, and KIT ligand, is synthesized
as a transmembrane protein that can be cleaved to yield a soluble,
bioactive form (Martin et al, 1990; Longley et al, 1997). An isoform
of SCF resulting from alternative splicing of exon 6 mRNA lacks
a major protease sensitive site and tends to remain membrane bound.
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a total of four mutations in an intracellular juxta-
membrane coding region that is completely conserved
among vertebrates. In addition, two mutations were
found in three mast cell lines derived from two addi-
tional dogs. One mutation from one line matched that
found in situ in one of the tumors. The second was
found in two lines derived from one dog at different
times, indicating that the mutation was present in
situ in the animal. All five mutations cause high
spontaneous tyrosine phosphorylation of KIT. Our
study provides in situ evidence that activating c-KIT
juxtamembrane mutations are present in, and may
therefore contribute to, the pathogenesis of mast cell
neoplasia. Our data also suggest an inhibitory role for
the KIT juxtamembrane region in controlling the
receptor kinase activity. Keywords: c-KIT/in situ/masto-
cytosis/receptor tyrosine kinase/stem cell factor. J Invest
Dermatol 112:165–170, 1999
As with activation of other receptor tyrosine kinases (Ullrich
and Schlessinger, 1990), SCF binding induces KIT dimerization
and activates its intrinsic kinase activity, resulting in receptor
autophosphorylation (Blume-Jensen et al, 1991; Lev et al, 1992).
The activated KIT then binds and phosphorylates a class of
intracellular substrate proteins, initiating a signaling cascade that
culminates in a wide array of biologic activities, including
proliferation, migration, maturation, and survival of hematopoietic
stem cell, mast cell, melanocyte, and germ cell lineages (Brizzi et al,
1994; Galli et al, 1994; Serve et al, 1994, 1995; Linnekin et al,
1997; Price et al, 1997). KIT can be constitutively activated by
autocrine SCF stimulation (Kondoh et al, 1995) or in a SCF-
independent manner involving mutations in the receptor (Furitsu
et al, 1993; Tsujimura et al, 1994, 1996; Hirota et al, 1998).
Expression of the activating KIT mutants in murine interleukin-
3-dependent cell lines leads to factor-independent growth and
aggressive in vivo behavior of the cells (Kitayama et al, 1995;
Tsujimura et al, 1996; Hirota et al, 1998), suggesting that constitu-
tively activated KIT is oncogenic.
Human mastocytosis, or mast cell disease, is a heterogeneous set
of conditions characterized by increased numbers of mast cells in
various organs (Longley et al, 1995). Mast cell neoplasms occur in
both humans and animals. In dogs, mast cell neoplasms are called
mastocytomas, and the disease is common, representing 7%–21%
of canine tumors (Priester, 1973; Cohen et al, 1974). A distinction
must be drawn between human mastocytosis, which is usually
transient or indolent (Longley et al, 1995), and canine mast cell
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neoplasia, which behaves unpredictably and is often aggressive and
metastatic (Macy and MacEwen, 1989). For instance, human
solitary mastocytomas essentially never metastasize; in contrast,
µ50% of canine mastocytomas behave in a malignant fashion, as
estimated by Hottendorf and Nielsen (1969) after review of 46
published reports of tumors in 938 dogs. KIT’s involvement in the
pathogenesis of mastocytosis is suggested by the observation that
several mutations resulting in constitutive activation of KIT have
been detected in a number of mast cell lines. For instance, a point
mutation in human c-KIT (causing substitution of Val for Asp816
in the phosphotransferase domain and receptor autoactivation)
occurs in HMC-1, a long-term human mast cell leukemia line
(Furitsu et al, 1993) and in the corresponding codon in two rodent
mast cell lines (Tsujimura et al, 1994, 1995). Moreover, this
activating mutation has been identified in situ in some cases of
human mastocytosis (Nagata et al, 1995; Longley et al, 1996). Two
other activating mutations have been found in another region of
KIT, the intracellular juxtamembrane region. One results in
Val560Gly substitution in the human HMC-1 mast cell line (Furitsu
et al, 1993), and the other eliminates seven amino acids (Thr573–
His579) in a rodent mast cell line called FMA3 (Tsujimura et al, 1996).
The significance of these two juxtamembrane region mutations is
unclear, as they have not been identified in situ.
To determine whether c-KIT juxtamembrane mutations are
present in mast cell neoplasms in situ and may therefore contribute
to their pathogenesis, we examined c-KIT cDNA from dog
mastocytoma tissues and cell lines. We report herein the complete
sequence of canine c-KIT, and the development of a model of KIT
structure. We also identify five novel juxtamembrane mutations
causing constitutive activation of KIT, which suggest a key region
involved in negative control of the receptor kinase activity, and
show that activating c-KIT juxtamembrane mutations are common
in canine mast cell neoplasms. This provides the first in situ evidence
that such mutations may play a part in the pathogenesis of mast
cell neoplasia.
MATERIALS AND METHODS
Materials Recombinant human (rh) and canine (rc) SCF, murine
monoclonal and rabbit polyclonal anti-human KIT antibody, and wild-
type (WT) human full-length c-KIT cDNA/pSPORT1 plasmid were
provided by Amgen (Thousand Oaks, CA). Mouse anti-phosphotyrosine
(pTyr) monoclonal antibody was purchased from Upstate Biotechnology
(Lake Placid, NY). Human SCF cDNA/pBluescript plasmid was provided
by Dr. Douglas Williams (Immunex, Seattle, WA).
Canine mastocytoma tissues and cells Six mastocytomas freshly
excised from six dogs were snap-frozen in OCT medium and cryostat-
sectioned. An additional mastocytoma removed from a seventh dog was
grown as a solid tumor in the dermis of a BALB/C athymic mouse prior
to being frozen. Three dog mastocytoma cell lines (BR, C1, and C2) were
established in long-term culture after initial serial passaging in the skin of
BALB/C athymic mice from skin mastocytomas of two additional dogs
(Lazarus et al, 1986; DeVinney and Gold, 1990). C1 and C2 originated
from tumors harvested at separate times from one dog. These cells were
cultured in Dulbecco’s modified Eagle’s medium supplemented with 2%
bovine calf serum and 0.25 mg per ml histidine. As control KIT-positive
cells, normal human melanocytes provided by Yale Skin Disease Research
Center (New Haven, CT) were grown in F10 medium with 10% bovine
calf serum. COS-7 cells were cultured in Dulbecco’s modified Eagle’s
medium with 10% bovine calf serum. Follow-up is only available on the
dog from which the C1 and C2 cell lines were derived which died of its
tumor. The sources of the BR cell line and the individual tumors were all
lost to follow-up.
Screening for mutations After RNA extraction, cDNA was synthe-
sized by reverse transcriptase using random hexamers as previously described
(Longley et al, 1991, 1996). c-KIT cDNA were amplified in the presence
of 1 µM of primers (see below) with Taq DNA polymerase for 30 cycles
of 1 min at 95°C, 1 min at 55°C, and 1 min at 72°C. Dideoxysequencing
was performed directly from gel-purified polymerase chain reaction ampli-
mers, or individual cDNA subcloned into plasmids using the TA Cloning Kit
(Invitrogen, Carlsbad, CA) by the W.M. Keck Foundation Biotechnology
Resource Laboratories at Yale University, the Biomolecular Resource
Center at the University of California at San Francisco, and the Skin
Disease Research Center of the Department of Dermatology of Columbia
University. Sequencing of mastocytoma c-KIT focused on the juxtamem-
brane and phosphotransferase coding regions using primer pairs: 59-
CAAATCCATCCCCACACCCTGTTCAC-39 (1564–1589) and 59-
CCATAAGCAGTTGCCTCAAC-39 (1850–1831); 59-TGTATTCA-
CAGAGACTTGGC-39 (2383–2402) and 59-GGCTGAGCATCCGG-
AAGCCT-39 (2695–2676). The numbers in parentheses refer to human
c-KIT cDNA (Yarden et al, 1987). The entire KIT coding region was
sequenced from cDNA prepared from normal dog lung mRNA.
cDNA construction and transfection Mutations identified in dog
mastocytomas (Trp556Arg, Leu575Pro, ∆Trp556–Lys557, and ∆Val558) were
reproduced in human c-KIT cDNA in the pcDNA3 mammalian expression
vector (Invitrogen) using the Quikchange Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA). Human c-KIT was used as the juxtamembrane
amino acids are completely conserved in mammals (see Results section).
COS-7 cells (90% confluent in 10-cm plate) were transfected with 5 µg
plasmid using 15 µl LipofectAMINE (Life Technologies, Gaithersburg,
MD) in serum-free medium for 5 h. An equal volume of medium with
20% bovine calf serum was then added and cells incubated overnight,
followed by 8–24 h culture in regular medium prior to protein expression
and tyrosine phosphorylation assay.
Immunoprecipitation and immunoblotting For SCF stimulation
experiments, cells were serum-starved for 18 h before incubation with
SCF. Cells were harvested in lysis buffer containing 1% Triton X-
100, 50 mM HEPES (pH 7.5), 150 mM NaCl, 10% glycerol, 1 mM
phenylmethylsulfonyl fluoride, 10 µg leupeptin per ml, 10 µg aprotinin
per ml , and 1 mM Na orthovanadate. Centrifugation-clarified cell lysates
were immunoblotted as total cell lysates (see below) or immunoprecipitated
for 1.5 h at 4°C with mouse anti-human KIT antibody and protein A
agarose. Immunoprecipitates were washed with lysis buffer and heat-eluted
in sodium dodecyl sulfate sample buffer. Samples were fractionated by
7.5% sodium dodecyl sulfate-polyacrylamide gel electrophoresis, transferred
on to polyvinylidene difluoride membrane, blocked by 5% bovine serum
albumin in Tris-buffered saline (50 mM Tris–HCl, pH 7.5, and 150 mM
NaCl) plus 0.1% Tween-20 (TBST), and probed with rabbit anti-human
KIT or mouse anti-pTyr antibody for 1 h, followed by washing with
TBST. Membranes were incubated in TBST with horseradish peroxidase-
linked secondary antibody for 45 min, washed, and antigen–antibody
complexes detected using the ECL System (Amersham, Arlington Heights,
IL). Anti-pTyr blots were stripped in 100 mM β-mercaptoethanol, 2%
sodium dodecyl sulfate, and 62.5 mM Tris–HCl (pH 6.7) at 50°C for
30 min, then reprobed with rabbit anti-human KIT antibody.
Detection of SCF mRNA SCF mRNA was detected by reverse
transcriptase–polymerase chain reaction, followed by Southern blotting with
a SCF-specific oligonucleotide probe and by direct amplimer sequencing.
Canine SCF primers correspond to nucleotides 191–209 and 607–588
(Shull et al, 1992), and the probe to human bases 301–367 (Martin
et al, 1990).
Molecular model generation A low-resolution homology model of
the intracellular canine KIT tyrosine kinase domains was constructed with
assistance from an automated protein modeling tool (ProMod) and server
(Swiss-Model) (Peitsch, 1996). The X-ray diffraction-derived coordinates
of the fibroblast growth factor (FGF) receptor tyrosine kinase domain
(Mohammadi et al, 1996) (1FGK in the Brookhaven Protein Data Bank)
served as a template for the model. Among available experimentally defined
tyrosine kinase structures, 1FGK is most homologous to KIT, as determined
by alignments with BLAST and FastA algorithms (Altschul et al, 1990).
First-approach alignments were checked in a process that included a
comparison of sequences conserved in other tyrosine kinases. The model
was then optimized by Swiss-Model, which idealizes bond geometry and
removes unfavorable nonbonded contacts by energy minimization with
CHARMM. The resulting coordinate files were displayed using the
RasMol molecular visualization program.
RESULTS
Canine c-KIT cDNA and protein sequence Overall, the
deduced amino acid sequence of normal dog KIT shows
identity of 93%, 88%, 81%, and 64% compared with cat, human,
mouse, and chicken KIT, respectively. Conservation is less in the
extracellular domain than in the intracellular domains. For example,
dog and human KIT are 78% identical in the 519/520 extracellular
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Figure 1. Nucleotide and deduced amino acid sequence of canine KIT. Predicted extracellular domain cysteines are shaded (the first Cys lies in
the signal peptide). Asn residues at consensus glycosylation sites are marked with asterisks (*). The predicted transmembrane domain is shaded. Residues
affected by the mis-sense mutations and deletions reported in this work lie within black boxes. A peptide repeated in the inserted sequence in C1 and
C2 mastocytoma cells is underlined. The site of the 48 bp C1/C2 nucleotide insertion is shown by a caret ( ∧ ). The normal dog KIT cDNA sequence
has been deposited in the GenBank database (accession number AF044249).
Table I. c-KIT juxtamembrane mutations in canine mastocytomas
WT Base change Amino acid change
Tissue
DS 2 6 bp deletion (1694–1699) ∆Trp556–Lys557
AG 2 3 bp deletion (1700–1702) ∆Val558
SW 2 T→C transition (1694) Trp556Arg
T→C transition (1752) Leu575Pro
Cell line
BR 1 T→C transition (1752) Leu575Pro
C1, C2 1 48 bp insertion (1784–1785) 1TYPTQLPYDHKWEFPR
domain residues but are 97% identical in the 433 intracellular
domain residues. In mammalian KIT (human, dog, cat, cow, goat,
rat, and mouse), the 38 residues of the intracellular juxtamembrane
region (amino acids 543–580 in Fig 1) are identical as are all but
one (Ile/Val661) of the adjacent 104 residues in the ATP-binding
domain. We used Trp581–Glu582 as the beginning of the kinase
domain, as defined by the crystal structure of FGF receptor kinase
(Mohammadi et al, 1996). Residues 768–914 comprise another
high-homology region (96% identical in alignments of mammalian
KIT), corresponding to the phosphotransferase domain. These
lengthy regions, which are intolerant of sequence variation among
different species, appear fundamental for concerted receptor func-
tion. The 12 extracellular domain cysteines (plus another in the
signal peptide) are conserved in dog and human KIT, as are nine
of 11 predicted canine N-linked glycosylation sites.
Mutations of c-KIT in dog mastocytomas We sequenced c-
KIT cDNA generated from mastocytoma tissues from seven dogs
(DS, AG, SW, RT, KR, LL, MN) and three mast cell lines derived
from two additional dogs (BR, C1, C2). Three of the tissue samples
showed four mutations clustered in the intracellular juxtamembrane
coding region (Fig 1 and Table I). Sample DS had a 6 bp deletion
eliminating Trp556–Lys557. Sample AG contained a 3 bp deletion
eliminating Val558. We found no WT sequence in either sample,
suggesting functional loss of one (presumably WT) allele. Sample
SW was heterozygous for point mutations in separate alleles: one
substituting Arg for Trp556 and the other substituting Pro for
Leu575. The Leu575Pro mutation also was present in cells of the
BR line, which was derived from a different dog. The C1 and C2
cell lines, derived, respectively, from early- and late-stage tumors
of one dog, both contained a 48 bp insertion between nucleotides
1784 and 1785, which are, respectively, the first and second base
of codon 586 in the proximal ATP-binding domain (Fig 1). Except
for the first 3 bp, the inserted nucleotide sequence is a direct repeat
of the segment immediately preceding the site of insertion. Deduced
amino acids 3–16 of the inserted sequence (Table I) are a repeat
of residues 572–585 of normal dog KIT (Fig 1). All the three cell
lines (BR, C1, and C2) were heterozygous for their respective
mutations, with the other allele being WT in the region of the
identified mutations. The mutations in the mastocytoma tissues
clearly developed in situ and could contribute to the pathogenesis
of mast cell neoplasms in the animals in which they developed.
Likewise, the detection of the same 48 bp insertion in both C1
and C2 cell lines, which were derived separately from the same
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Figure 2. Predicted structure of canine
KIT. (a) Extracellular immunoglobulin-like
loops I–V are depicted as partially closed circles;
the location of cysteines (S-S) and potential
glycosylation sites (*) are marked. Intra-
cellularly, the juxtamembrane, ATP-binding,
kinase insert, phosphotransferase, and C-ter-
minal tail regions are indicated. (b) A model
of canine KIT intracellular tyrosine kinase
(and a portion of the juxtamembrane region)
prepared by homology modeling using the
known structure of the FGF receptor tyrosine
kinase (Mohammadi et al, 1996). In the ATP-
binding and phosphotransferase lobes of the
tyrosine kinase, β (lightly shaded ribbons) and
α (darkly shaded ribbons) secondary structure
predominate, respectively. The site of the 16-
amino acid insertion in C1 and C2 cells is
indicated, as is the location of the Leu575Pro
substitution detected in SW mastocytoma and
BR cells. The locations of critical nucleotide
binding and catalytic loops and of the ‘‘activa-
tion loop,’’ which contains tyrosine residues
thought to be phosphorylated and is a site of a
previously recognized KIT activating mutation
(Furitsu et al, 1993), are indicated.
animal at different times, indicates that the mutation was present
in the original tumors. Therefore, we link all five mutations to
dog mastocytomas in situ.
Limited sequencing of the region encompassing codons 514–
609 in the other four dog mastocytomas showed only WT
sequences. As an activating point mutation has previously been
identified in codon 816 in the phosphotransferase domain in
some human patients with mastocytosis (Nagata et al, 1995; Longley
et al, 1996), we also sequenced cDNA corresponding to codons
787–890 but no mutations were found.
The structure of canine KIT and location of identified mutations
are depicted schematically in Fig 2. The N-terminal portion of
the juxtamembrane region, the kinase insert, and the C-terminal
tail are omitted from the ribbon model due to the lack of FGF
receptor-homologous sequence in these regions.
Juxtamembrane mutations activate KIT To determine the
functional significance of the four novel mis-sense and deletion
mutations, we made equivalent mutations in human c-KIT cDNA
and expressed the constructs in COS-7 cells. COS cells have
previously been used for KIT function assays because they express
neither endogenous KIT nor SCF (Reith et al, 1991; Serve et al,
1994; Price et al, 1997). We used a human c-KIT cDNA as we
have had extensive experience with one which was in hand, and
as the juxtamembrane region amino acids we were studying are
100% conserved in all mammals studied. Figure 3(b) shows the
expression of WT and mutant KIT. KITWT was expressed as
proteins of 145 kDa and 125 kDa, which represent cell-surface
(fully glycosylated) and intracellular (partially glycosylated) forms,
respectively (Majumder et al, 1988; Nocka et al, 1989, 1990). The
four mutant KIT were also expressed as two protein products
corresponding to KITWT, except that the electrophoretic mobility
of ∆Trp556–Lys557 mutant was retarded by µ5 kDa. In contrast to
KITWT, the larger isoforms of mutant KIT were apparently less in
the steady state. The altered expression pattern of these mutants is
similar to the expression of KIT containing an Asp816Val activating
mutation (Furitsu et al, 1993), which has an accelerated turnover
of its cell-surface form (Moriyama et al, 1996).
In the absence of rhSCF, the 145-kDa KITWT showed a low
basal level of spontaneous tyrosine phosphorylation (Fig 3a), which
has also been observed by previous studies (Reith et al, 1991; Serve
et al, 1994). The four mutant KIT, however, exhibited high levels
of spontaneous tyrosine phosphorylation of both size isoforms;
phosphorylation of the larger forms was at least 10-fold higher than
that of KITWT (density quantitated after normalizing the difference
in protein expression shown in Fig 3b). rhSCF stimulation at
100 ng per ml for 10 min led to an increase in phosphorylation of
KITWT and a decrease in its protein amount. The latter is consistent
with SCF-induced KIT downregulation (Yee et al, 1993, 1994).
In contrast, the rhSCF stimulation reduced both the degree of
phosphorylation and the amount of the larger isoforms of mutant
KIT, without affecting the smaller isoforms. One explanation for
these results is that the mutant receptor phosphorylation is saturated.
Taken together, the results indicate that the four juxtamembrane
mutations identified in canine mastocytomas are kinase-activating
mutations.
Because of technical difficulties associated with reproducing the
48 base insert in an intact cDNA, we assayed KIT tyrosine
phosphorylation in C1 and C2 cells themselves to determine the
effect of the fifth mutation. As rcSCF stimulates human KIT
(unpublished results), we used normal human melanocytes as KIT-
positive control cells. Figure 4(b) shows both C1 and C2 cells
expressed immunoreactive KIT protein corresponding to human
KIT. In the absence of rcSCF, the C1 and C2 cell KIT showed
high levels of spontaneous tyrosine phosphorylation, µ5-fold higher
than normal human KIT (Fig 4a). Although the human receptor
underwent remarkable tyrosine phosphorylation in response to
rcSCF stimulation, the mutated canine KIT showed only slight
increases in phosphorylation, which was already µ80% of the
maximum levels obtained by ligand stimulation. Concentrations of
rcSCF up to 500 ng per ml did not significantly increase the C1
and C2 KIT phosphorylation over that seen with 100 ng per ml
(data not shown). The relative contributions of mutant and WT
KIT to the observed phosphorylation are unclear from these data.
To rule out possible autocrine SCF production as a source of
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Figure 3. KIT is highly activated by juxtamembrane mutations.
(a) Anti-pTyr blot of immunoprecipitated human WT and juxtamembrane-
mutated KIT transiently expressed in COS-7 cells treated, or not, with
rhSCF (100 ng per ml, 10 min) following serum starvation reveals that the
four mutants are spontaneously phosphorylated (lanes 3, 5, 7, 9) at strikingly
high levels compared with normal receptor (lane 1). (b) Reprobing the
upper blot (after stripping) with anti-KIT antibody shows relative amount
of two isoforms of WT (lanes 1–2) and mutant (lanes 3–10) KIT. Molecular
weight marker positions (in kDa) are indicated.
receptor activation, we sought mRNA encoding SCF in the dog
cells. Reverse transcriptase–polymerase chain reaction using primers
specific for canine SCF yielded no products from C1 and C2 cells,
but amplimers were unexpectedly produced from the BR dog
mastocytoma cell line (data not shown). These amplimers have
sequence identical to that previously published for dog SCF (Shull
et al, 1992) (data not shown), and validate the use of these
polymerase chain reaction primers to rule out SCF production by
C1 and C2 cells. Although endogenous SCF could activate KITWT
in BR cells, it is not necessary to activate the mutant receptor
because, as we have shown in Fig 3, the Leu575Pro mutated KIT
found in this cell line was spontaneously activated. The lack of
detectable SCF mRNA transcripts in C1 and C2 cells indicates
that autocrine SCF stimulation is not responsible for the constitutive
KIT activation seen in these cells, leaving the insertion mutation
as the most likely cause.
DISCUSSION
This study identifies five novel activating c-KIT mutations in
canine mastocytomas and provides in situ evidence that c-KIT
Figure 4. KIT in C1 and C2 cells are highly autophosphorylated.
(a) Anti-pTyr blot of total cell lysates of human melanocytes (HM) and
C1 and C2 cells incubated, or not, with rcSCF (100 ng per ml, 10 min)
following serum starvation shows that spontaneous phosphorylation of
canine KIT (lanes 3, 5) is markedly higher than that of normal human KIT
(lane 1) and µ80% of rcSCF-induced phosphorylation of the canine
receptors (lanes 4, 6). (b) Reprobing the upper blot (after stripping) with
anti-human KIT antibody substantiates comparable protein amount of
human (lanes 1–2) and canine (lanes 3–6) receptors. Marker protein positions
(in kDa) are indicated.
juxtamembrane mutations are present in the development of mast
cell neoplasms. Because autoactivated KIT mutants can transform
cell lines to factor-independent growth in vitro and confer tumori-
genicity in vivo (Kitayama et al, 1995; Tsujimura et al, 1996; Hirota
et al, 1998), it appears likely that they contribute to the pathogenesis
of mast cell neoplasia. Canine mast cell neoplasms often behave
aggressively and, in the present survey, are highly associated with
juxtamembrane mutations. Mastocytosis in humans, in contrast, is
generally more indolent and only a single Asp816Val mutation in
the phosphotransferase domain has been demonstrated in situ
(Nagata et al, 1995; Longley et al, 1996). Chromosomal abnormali-
ties, such as trisomies of chromosomes 8 and 9, have been identified
in human patients with mastocytosis (Lishner et al, 1996). It may
be that such aberrations also contribute to the pathogenesis of
mastocytosis, especially with regard to whether or not the disease
behaves in an aggressive fashion. Interestingly, a juxtamembrane
point mutation has been found in the human mast cell line HMC-1
(Furitsu et al, 1993), which was derived from an extremely rare
and aggressive case of human mast cell leukemia (Butterfield et al,
1988). Whether the association of different sorts of mutations
with more or less aggressive mast cell disease represents a direct
consequence of the type of mutation is unclear, as is whether or
not activating c-KIT mutations by themselves are sufficient to cause
mast cell neoplasia. Although they have not been identified in
human mast cells in situ, c-KIT juxtamembrane activating mutations
do occur in human tumors, as a recent study has identified four
deletions and one mis-sense mutation (Val559Asp substitution)
within this region in human gastrointestinal stromal tumors (Hirota
et al, 1998).
The substantial increase in spontaneous tyrosine phosphorylation
of KIT caused by the juxtamembrane mutations shown in Fig 3
suggests that an intrinsic inhibitory constraint of the receptor
kinase is relieved by these mutations. Replacement of Trp (an
amphipathic residue) at position 556 with an Arg (comparable in
size but charged) causes autoactivation, suggesting that the Trp’s
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hydrophobic side chain is important for the inhibition. Correct
aligning and folding of other residues appear crucial as well, because
deletion of Trp556–Lys557 or Val558, or substitution of Pro for
Leu575 have similar effects. Consistent with our results are the
autoactivated KIT with mutations in this region in the HMC-1
(Furitsu et al, 1993) and FMA3 (Tsujimura et al, 1996) cell lines
and in gastrointestinal stromal tumors (Hirota et al, 1998). In light
of the trans-phosphorylation model of activation of receptor tyrosine
kinases (Ullrich and Schlessinger, 1990), an intact juxtamembrane
region may keep the accessible surface area for dimer formation at
a minimum so that trans-phosphorylation is deterred. To test this
hypothesis, we used chemical cross-linking reagents to detect
ligand-independent dimers of the mutant KIT, but our results were
inconclusive, possibly due to the transient nature of receptor
dimerization and/or the low efficiency of cross-linking (data not
shown). It is also possible that the mutant KIT are cis-phosphoryl-
ated, and the juxtamembrane region may stabilize the adjacent kinase
domain in an auto-repressed conformation through intramolecular
interactions. Inhibition of kinase activity by additional domains
through intramolecular interactions, although not reported for
receptor tyrosine kinases, has recently been shown in the crystal
structure of Src (Xu et al, 1997) and Hck tyrosine kinases (Sicheri
et al, 1997).
In addition to modulating kinase activity, the KIT juxtamembrane
region has recently been shown to interact with two intracellular
signaling molecules: the Src family member Lyn (Linnekin et al,
1997) and CsK-homologous kinase (Price et al, 1997). Studies on
substrate-binding specificities of KIT juxtamembrane mutants may
add to our understanding of the molecular mechanisms underlying
KIT signaling pathways and mast cell proliferative disorders.
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